drugset / Trial / NCT04713072
A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled, dose finding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to investigate the efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035 in adult patients with PsA.
Timeline
- Start
- 2020-08-04
- Primary completion
- 2021-10-01
- Completion
- 2022-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Izokibep | Protein / enzyme biologic | 40 mg | Subcutaneous |
| Subject | Izokibep | Protein / enzyme biologic | 80 mg | Subcutaneous |